Manufacturer
PHARMANIAGA LIFESCIENCE SDN. BHD.
Contents
Ranitidine HCl
Indication
Short-term treatment of active duodenal & benign gastric ulcer. Maintenance therapy for duodenal & gastric ulcer patients at reduced dosage. GERD & pathological hypersecretory conditions eg, Zollinger-Ellison syndrome.
Instruction
May be taken with or without food.
Drug interaction
Altered prothrombin time and increased serum concentration with coumarin anticoagulants (e.g. warfarin). May reduce the excretion and increase plasma concentrations of procainamide and N-acetylprocainamide (high dose ranitidine). May alter the absorption of pH-dependent drugs which may result in either an increase in absorption (e.g. triazolam, glipizide, midazolam) or decrease in absorption (e.g. atazanavir, gefitnib, ketoconazole, delaviridine). Decreased absorption with co-administration of high dose sucralfate.